JP2008508899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508899A5 JP2008508899A5 JP2007525666A JP2007525666A JP2008508899A5 JP 2008508899 A5 JP2008508899 A5 JP 2008508899A5 JP 2007525666 A JP2007525666 A JP 2007525666A JP 2007525666 A JP2007525666 A JP 2007525666A JP 2008508899 A5 JP2008508899 A5 JP 2008508899A5
- Authority
- JP
- Japan
- Prior art keywords
- replication
- adenovirus
- nucleic acid
- composition according
- deficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 13
- 239000002245 particle Substances 0.000 claims 11
- 230000002950 deficient Effects 0.000 claims 8
- 230000010076 replication Effects 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 2
- 230000005030 transcription termination Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60032804P | 2004-08-09 | 2004-08-09 | |
| PCT/US2005/027658 WO2006020480A2 (en) | 2004-08-09 | 2005-08-05 | Adenoviral vector compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508899A JP2008508899A (ja) | 2008-03-27 |
| JP2008508899A5 true JP2008508899A5 (enExample) | 2008-09-18 |
Family
ID=35908044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525666A Withdrawn JP2008508899A (ja) | 2004-08-09 | 2005-08-05 | アデノウイルスベクター組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080063656A1 (enExample) |
| EP (1) | EP1786904A4 (enExample) |
| JP (1) | JP2008508899A (enExample) |
| CN (1) | CN1993462A (enExample) |
| AU (1) | AU2005274059A1 (enExample) |
| CA (1) | CA2575163A1 (enExample) |
| WO (1) | WO2006020480A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| ES2685823T3 (es) | 2008-07-16 | 2018-10-11 | Baylor Research Institute | Anticuerpos antagonistas anti-CD40 |
| GB0823497D0 (en) * | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| DK2521776T3 (en) | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
| CA2786377C (en) | 2010-01-05 | 2018-02-27 | Vascular Biogenics Ltd. | Compositions and methods for treating malignant gliomas employing viral vectors encoding a fas-chimera |
| CN103242433B (zh) * | 2012-02-14 | 2016-12-14 | 中国医学科学院病原生物学研究所 | 一种腺病毒非结构蛋白免疫原、其抗体及应用 |
| EP4295153A4 (en) * | 2021-02-21 | 2025-11-05 | Fed State Budgetary Inst Nat Res Centre For Epidemiology And Microbiology Named After The Honorary A | USE OF THE AGENT TO INDUCT IMMUNITY AGAINST SARS-CoV-2 |
| KR20240036508A (ko) * | 2021-05-13 | 2024-03-20 | 포지 바이올로직스, 인크. | 아데노바이러스성 헬퍼 플라스미드 |
| EP4404947A4 (en) * | 2021-09-23 | 2025-12-10 | Sagittarius Bio Inc | Adenovirus and Methods of Using Adenovirus |
| WO2024026302A2 (en) * | 2022-07-26 | 2024-02-01 | Asimov Inc. | Compositions and methods for adeno-associated viral production |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| JP2005519959A (ja) * | 2002-03-13 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖに対する強化された免疫応答を誘導する方法 |
-
2005
- 2005-08-05 US US11/659,671 patent/US20080063656A1/en not_active Abandoned
- 2005-08-05 CN CNA2005800267346A patent/CN1993462A/zh active Pending
- 2005-08-05 CA CA002575163A patent/CA2575163A1/en not_active Abandoned
- 2005-08-05 WO PCT/US2005/027658 patent/WO2006020480A2/en not_active Ceased
- 2005-08-05 AU AU2005274059A patent/AU2005274059A1/en not_active Abandoned
- 2005-08-05 JP JP2007525666A patent/JP2008508899A/ja not_active Withdrawn
- 2005-08-05 EP EP05779520A patent/EP1786904A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508899A5 (enExample) | ||
| Gao et al. | State‐of‐the‐art human adenovirus vectorology for therapeutic approaches | |
| Yang et al. | Overcoming immunity to a viral vaccine by DNA priming before vector boosting | |
| Fausther-Bovendo et al. | Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important? | |
| Tatsis et al. | Adenoviruses as vaccine vectors | |
| Kaplan | Adenovirus-based cancer gene therapy | |
| Zhang et al. | Adenoviral vector-based strategies against infectious disease and cancer | |
| JP4787936B2 (ja) | 癌処理への使用のためのキメラアデノウィルス | |
| Wang et al. | Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy | |
| JP2014503206A5 (enExample) | ||
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| CA2477954A1 (en) | Means and methods for the production of adenovirus vectors | |
| JP2016513115A5 (enExample) | ||
| JP2009544318A5 (enExample) | ||
| JP2009515831A5 (enExample) | ||
| JP2002537816A5 (enExample) | ||
| Kreppel et al. | Capsid and genome modification strategies to reduce the immunogenicity of adenoviral vectors | |
| US20140140962A1 (en) | Viruses modified with unnatural moieties and methods of use thereof | |
| JP4843613B2 (ja) | 改良されたアデノウイルスベクターおよびその使用方法 | |
| Welsh | Gene transfer for cystic fibrosis | |
| JP2009523007A5 (enExample) | ||
| Tessarollo et al. | Nonreplicating adenoviral vectors: improving tropism and delivery of cancer gene therapy | |
| Giménez-Roig et al. | Codon usage and adenovirus fitness: implications for vaccine development | |
| Dharmapuri et al. | Engineered adenovirus serotypes for overcoming anti-vector immunity | |
| JP2008510493A (ja) | 腫瘍細胞の形質導入強化のための線維改変アデノウイルスベクター |